Potential remote measurement of C-peptide using a minimally invasive and convenient sampling technique
BACKGROUND: In clinical research, alternatives to venipuncture can reduce participant burden and increase accessibility and sampling opportunities for biomarkers. Residual pancreatic beta-cell function is assessed in clinical research and in diabetes care using fasting and stimulated C-peptide measurements, and changes are assessed over time. Operational, technical, and acceptability considerations of utilizing Tasso+ SST devices for C-peptide collection compared to venipuncture-derived serum samples were investigated. METHODOLOGY: Samples were collected from prospectively enrolled healthy participants via Third Generation Tasso+ SST micro-sampling devices and phlebotomy. Eleven fasted Tasso+ samples collected on-site or remote underwent alternative handling conditions and were evaluated for consistency, quality, and stability. Participants responded to device acceptability questionnaires. RESULTS: The Tasso+ SST micro-sampling device showed excellent concordance with simultaneous venipuncture-derived fasted C-Peptide, with concentration being largely conserved in healthy volunteers despite alternative sample handling. Delayed centrifugation over 72 hours caused no consequential degradation of C-peptide when kept at 4°C. Questionnaire responses indicate acceptable device usability and associated comfort levels. CONCLUSION: Fasting C-peptide levels can be accurately collected using micro-sampling collection techniques. Tasso+ C-peptide stability is seen when kept at 4°C. Micro-sampling devices can be used with shipping mechanisms (without centrifugation) to decrease participant burden, expand trial populations, and aid biomarker measurements.
Authors
- Fedelis Mutiso (ORCID: https://orcid.org/0000-0003-3420-6261)
- Allison B. Goldfine (ORCID: https://orcid.org/0000-0002-0345-1048)
- Nina Vujović
- Lili Yu (ORCID: https://orcid.org/0000-0002-2427-5784)
- Д. А. Михайлов
- Kathryn Duschean
- Arvind Kinhikar
- Emad Dumar
- Arkady Gusev
Institutions
- AbbVie (United States) (US)
- Novartis (China) (CN)
- AbbVie (Japan)
Publication Details
- Journal
- Bioanalysis
- Published
- 2026-07-24
- DOI
- https://doi.org/10.1080/17576180.2026.2690265
- Primary Topic
- Diabetes and associated disorders
- Type
- article
- Field-Weighted Citation Impact
- 0.00
Funders
- Novartis